HNRNPA1 and neoplasm: On day 15, modest and variable target engagement was observed in tumor biopsies at the 100-mg dose level, with a mean reduction (SE) of ADMA-hnRNP-A1 of 18.5% (9.6) in 4/6 patients by LC-MS and 2.08% (9.36) in 4/8 patients by IHC (Fig. 2c, d).